When Should a Linear Peptide Be Cyclized?

When a linear peptide has already shown good activity but is rapidly degraded in serum, is overly conformationally flexible, or has insufficient in vivo exposure, it is natural for a project team to consider “cyclizing it.” This direction has a solid scientific basis: by connecting two positions in the peptide chain, cyclization can restrict conformational space, reduce terminal exposure, and alter binding, stability, and membrane interactions. However, cyclic peptides are not the default upgraded version of linear peptides.

The same conformational constraint can lock a state close to the bioactive conformation, or it can lock an incorrect conformation; it may improve protease stability, or it may prevent key side chains from entering the binding interface; some macrocycles have better permeability, while others show no improvement because their charge, polarity, or conformation is unsuitable. At the same time, cyclization also adds protection, ring-closure, and purification steps. Cyclization is a structural constraint, not merely a chemical modification. Whether to cyclize should be a design decision based on the target, structure, and chemical constraints, rather than because “cyclic peptides look more advanced.”

When Cyclization Is Worth Considering

The most common scenario is that the parent peptide already has preliminary activity, but proteolytic stability or serum stability has become the main limitation. Closing the N-terminus and C-terminus or reducing backbone flexibility can sometimes reduce the opportunities for protease recognition and cleavage. However, if degradation is mainly concentrated at a clearly defined cleavage site, local D-amino acid substitution, N-methylation, or conservative residue substitution may be more direct and may more readily preserve the original binding.

A second favorable scenario is when there is relatively clear evidence for the active conformation, such as a peptide–protein complex structure, NMR information, a reliable structural model, or a binding mode validated by mutagenesis. In this case, sites that do not participate in key interactions and whose spatial geometry allows connection can be identified, and a crosslink can be used to stabilize the existing bioactive conformation. The design sequence should be to first identify the conformation that needs to be preserved, and then select a suitable cyclization method, rather than first deciding that a ring must be formed and then randomly selecting two residues to connect.

If a linear peptide samples a large number of conformations in the free state but must converge to a relatively defined state upon binding, conformational preorganization may reduce the conformational entropy cost during the binding process. However, this does not mean that cyclization will necessarily increase affinity; preorganization can provide an advantage only when the stabilized conformation is close to the true bound state and the linking group does not interfere with the interface.

Permeability Goals Require More Than “Ring Formation”

Some macrocyclic peptides can achieve better membrane permeability than their corresponding linear peptides through conformational shielding, intramolecular hydrogen bonds, appropriate N-methylation, and dynamic polar surface exposure. Such results have made cyclization an important tool in research on intracellular targets and oral peptides, but “cyclization” itself does not equal “improved permeability,” much less “oral availability.”

Molecular size, net charge, exposed polarity, N-methylation position, backbone hydrogen-bond donors, hydrophobic surface, and conformational dynamics all jointly influence transmembrane behavior. Excessively strong cationic or hydrophobic characteristics may also increase nonspecific membrane interactions, cytotoxicity, and hemolysis. Therefore, when permeability is the objective, multiple ring topologies should be evaluated together with linear controls, while solubility and safety indicators are also tested.

When Cyclization May Not Be a Good Choice

If target recognition requires induced fit, an extended conformation, or multiple binding modes, overly strong structural constraints may impair activity. Some linear peptides rely on flexibility to bypass surface obstacles or sequentially contact multiple regions; fixing such a peptide in a single geometry may remove precisely the degrees of freedom required for binding.

Unsuitable connection geometry is also a common cause of failure. Anchor distance, side-chain orientation, linker length, and ring size together determine the conformations that can be accessed after ring closure. A distance that is too short may generate high ring strain, while a distance that is too long may retain excessive freedom; even if a linker can be formed chemically, it may push key residues in the wrong direction. In the absence of structural information, it is difficult to distinguish whether the failure of a single cyclization design means “the cyclization concept is not applicable” or “this topology is not applicable,” so multiple designs usually need to be compared.

For a parent peptide that already has severe on-resin aggregation, multiple N-methyl residues, highly hydrophobic segments, difficult NCAAs, or complex side-chain protection, adding cyclization will further increase the difficulty of linear precursor synthesis, selective deprotection, ring closure, and separation. If the main objective is only to protect the termini or address a single cleavage site, terminal capping, local substitution, or D-amino acids may be more economical first-round experiments. Cyclization should solve a clearly defined problem and should not become a default operation without a hypothesis.

How the Main Cyclization Strategies Compare

Different linking chemistries change not only “whether a ring is formed,” but also ring size, bond stability, protection strategy, and the anchors that can be used. Common strategies can be compared as follows:

Cyclization method	Design features and potential advantages	Main limitations and risks
Disulfide cyclization	Suitable for sequences with appropriate Cys sites; oxidative ring-closure routes are widely used and can be used to mimic natural disulfide constraints	Sensitive to reducing environments; multi-Cys systems may undergo disulfide scrambling and form multiple isomers; chemical stability depends on the use environment
Head-to-tail cyclization	The N-terminus and C-terminus form a backbone amide bond, which can remove free termini and provide strong backbone constraint without requiring an additional side-chain bridge	Precursor geometry and sequence length have a significant effect; inefficient macrocyclization, epimerization, or intermolecular oligomerization may occur; route design is more complex
Lactam cyclization	A side-chain amine and a side-chain carboxylic acid form an amide bond; Lys, Orn, or Dab can be used with Asp, Glu, or specific NCAAs; the connection length is tunable and the bond is relatively robust	Appropriate orthogonal protection is required; anchor and linker geometry determine the conformation; ring strain may be generated or an incorrect state may be locked
Side-chain-to-side-chain cyclization	Thioether or other chemoselective linkages can be used, enabling selection of chemical stability according to the site and use environment	Reaction handles, selectivity, and residual functional groups need to be verified; the linking group may affect binding, solubility, and analysis
Side-chain-to-terminal cyclization, including side-chain-to-tail cyclization	A side-chain functional group is connected to the N-terminus or C-terminus, allowing a constraint to be established while retaining part of the backbone direction	The design space and protection strategy are relatively complex; whether the terminus and anchor participate in activity must first be confirmed

There is no “best cyclization method” independent of sequence and intended use. Disulfide is not necessarily simpler than lactam, and lactam is not inherently superior to disulfide; the choice depends on the target environment, required geometry, chemical stability, available residues, and synthetic route.

Smaller Ring Size Is Not Always Better

Ring size simultaneously affects ring strain, conformational freedom, side-chain orientation, ring-closure kinetics, and binding geometry. A ring that is too small may force the backbone to adopt a high-energy conformation, make the precursor difficult to cyclize, or cause key side chains to deviate from the bound state; although an overly large ring can more readily accommodate different conformations, it may fail to significantly reduce conformational entropy and may also retain the original flexibility problems of the linear peptide.

Useful ring size is determined by the target and the conformation. During design, more attention should be paid to whether the ring can accommodate the active conformation at a reasonable energy, whether the linking group interferes with the interface, and whether the required behavior is maintained in different solvent environments, rather than pursuing the smallest number of residues. For the same parent, comparing adjacent anchor combinations and different linker lengths is usually more reliable than betting on a theoretical “optimal size.”

How to Select Cyclization Sites

The first step is to protect functional residues. Based on mutagenesis data, conserved motifs, complex structures, or existing SAR, binding hotspots, recognition sites, catalysis-related residues, and key charge arrangements should be annotated. Unless there is a clear alternative, these positions are usually not suitable as crosslink anchors; a Lys or Cys that is chemically very convenient may still be the wrong choice if it is located at the binding interface.

If a complex structure or reliable model is available, candidate residues can be compared in terms of distance, side-chain orientation, solvent exposure, local secondary structure, and the risk of clashes with the target after connection. Anchors are preferably located at positions that do not directly contribute key binding interactions but can stabilize the target conformation through an appropriate linker. For α-helices, turns, or extended segments, the required connection geometries are not the same, and a single sequence spacing cannot be applied universally.

The second step is to retain alternative topologies. Shorter and larger rings, different anchor pairs, different linker lengths, or different chemistries can be designed simultaneously, and then screened from the three dimensions of structure, synthesizability, and experimental results. Cyclization is only one existing peptide optimization strategy; point mutation, D-amino acids, N-methylation, NCAAs, and terminal modifications should also be used as controls or combination approaches.

How AI and Three-Dimensional Modeling Can Help

AI and structure-based methods can help identify candidate anchors, compare ring geometry, evaluate whether the active conformation is likely to be retained, detect obvious spatial clashes, and prioritize different cyclization designs and conformational ensembles. When a complex structure is unavailable, models can also help generate multiple hypotheses that require experimental validation, avoiding completely random selection of connection positions.

The boundaries of these methods are equally important. A low-energy predicted conformation cannot accurately provide the actual cyclization yield, crude purity, isolated yield, serum stability, or true affinity, nor can it fully represent the effects of resin, solvent, concentration, and protecting groups on the ring-closure reaction. 3D geometry is suitable for strategy ranking, not as a guarantee of synthetic results; key conclusions still need to be confirmed through actual preparation, analysis, and functional experiments.

How Noncanonical Amino Acids Expand Cyclization Options

Noncanonical amino acids (NCAAs) can introduce orthogonal reaction handles, adjust side-chain length and ring size, alter local conformation, or form bonds that are more suitable for the target environment than certain natural linkages. Orn and Dab provide side-chain amines of different lengths, D-amino acids can alter local geometry and protease recognition, and N-methyl amino acids affect backbone hydrogen bonds and conformation; other validated handles can support specific chemoselective cyclization.

These residues cannot be treated as an open-ended alphabet to be combined arbitrarily. Design needs to simultaneously confirm protected building block availability, protecting-group orthogonality, coupling compatibility, ring-closure chemistry, purification, and cost. The role of noncanonical amino acids in drug development describes the value of expanding chemical space, while specific cyclization projects must incorporate available materials and practical routes into candidate screening.

Cyclization Design Must Include Synthesizability

A cyclic peptide with a theoretically more ideal structure is still not a good development candidate if the linear precursor is difficult to assemble, selective deprotection is uncontrollable, ring closure generates multiple byproducts, or the target cannot be purified. An actionable assessment should cover linear precursor synthesis, deprotection, macrocyclization, side reactions and oligomerization, crude purity, preparative separation, and final isolated yield.

Cyclization yield is also not the only criterion. Even if a ring-closure reaction occurs to a greater extent, project costs may still be high if the main product is difficult to separate from mismatched products, epimers, or oligomers. The previous article “Why Must AI-Designed Peptides Still Undergo ‘Synthesizability’ Screening?” further explains how SPPS, difficult couplings, NCAA materials, and purification risks enter design prioritization.

Placing Cyclization Within Multi-Objective Optimization

Cyclization is not an independent objective. Candidates still need to be compared simultaneously in terms of activity, affinity, stability, permeability, solubility, toxicity, hemolysis, synthesis difficulty, and purification difficulty. For example, Candidate A may retain affinity and moderately improve stability; Candidate B may have higher stability, but the precursor and ring closure are more difficult; Candidate C may have better permeability potential but poorer solubility. “A tighter structure” alone cannot determine which candidate is more suitable for the project.

A more reasonable strategy is to retain multiple linear and cyclic candidates that represent different trade-offs, set priorities around the current bottlenecks, and compare them within the same set of experiments. In this way, even if a particular cyclization topology fails, it is possible to determine whether the problem arises from the active conformation, the linking chemistry, or the overall cyclization hypothesis, rather than obtaining only an uninterpretable negative result.

Recommended Design Workflow for Cyclizing Linear Peptides

A complete workflow can be summarized as follows:

Active linear peptide → define the problem to be addressed → mark key residues → determine whether cyclization is appropriate → select candidate anchor points → compare cyclization chemistries → structural evaluation → synthesizability review → select multiple cyclic designs → synthesis → purification and QC → activity and stability experiments → iteration

Apollomics can evaluate whether cyclization is worthwhile and which approaches should be prioritized for experimental testing based on the sequence of an existing linear peptide, known activity, target structure, binding mode, residue constraints, cyclization chemistry, NCAAs, and synthetic feasibility, while also connecting the process with custom peptide and cyclic peptide synthesis, purification and HPLC, and LC-MS quality analysis. The service logic is Linear Peptide → Cyclization Design → Structural Review → Synthesizability Review → Synthesis → QC → Experimental Validation.

Conclusion

Whether a linear peptide is worth cyclizing depends on the problem it needs to solve and whether there are structural constraints that can preserve the active conformation while also being achievable through a rational chemical route. Cyclization can be a powerful tool for improving stability and conformational control, but it may also be counterproductive because of incorrect geometry, excessive constraint, or synthetic complexity.

Good cyclization design is not about finding a pair of sites that appear connectable, but about proposing multiple interpretable, synthesizable, and comparable options, and using experiments to determine which trade-off is truly appropriate for the project.

For more background on the basic design of cyclic peptides, see Cyclic Peptide Design Guide: Why Cyclic Peptides Are Becoming Increasingly Important.